Switch theme
Sign up to access all valuation multiples
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
1991
9.7K+
LTM Revenue $3.4B
LTM EBITDA $627M
$7.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bruker has a last 12-month revenue (LTM) of $3.4B and a last 12-month EBITDA of $627M.
In the most recent fiscal year, Bruker achieved revenue of $3.4B and an EBITDA of $439M.
Bruker expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bruker valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| Gross Profit | $1.8B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 49% | XXX | XXX | XXX |
| EBITDA | $627M | XXX | $439M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 13% | XXX | XXX | XXX |
| EBIT | $525M | XXX | $379M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $364M | XXX | $113M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.9B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bruker's stock price is $37.
Bruker has current market cap of $5.6B, and EV of $7.5B.
See Bruker trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.5B | $5.6B | XXX | XXX | XXX | XXX | $2.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bruker has market cap of $5.6B and EV of $7.5B.
Bruker's trades at 2.2x EV/Revenue multiple, and 17.1x EV/EBITDA.
Equity research analysts estimate Bruker's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bruker has a P/E ratio of 15.3x.
See valuation multiples for Bruker and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.6B | XXX | $5.6B | XXX | XXX | XXX |
| EV (current) | $7.5B | XXX | $7.5B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 11.9x | XXX | 17.1x | XXX | XXX | XXX |
| EV/EBIT | 14.3x | XXX | 19.8x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.3x | XXX | 49.2x | XXX | XXX | XXX |
| EV/FCF | 36.1x | XXX | 55.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBruker's last 12 month revenue growth is 4%
Bruker's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Bruker's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bruker's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bruker and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 27% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bruker acquired XXX companies to date.
Last acquisition by Bruker was XXXXXXXX, XXXXX XXXXX XXXXXX . Bruker acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bruker founded? | Bruker was founded in 1991. |
| Where is Bruker headquartered? | Bruker is headquartered in United States of America. |
| How many employees does Bruker have? | As of today, Bruker has 9.7K+ employees. |
| Who is the CEO of Bruker? | Bruker's CEO is Dr. Frank H. Laukien,PhD. |
| Is Bruker publicy listed? | Yes, Bruker is a public company listed on NAS. |
| What is the stock symbol of Bruker? | Bruker trades under BRKR ticker. |
| When did Bruker go public? | Bruker went public in 2000. |
| Who are competitors of Bruker? | Similar companies to Bruker include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Bruker? | Bruker's current market cap is $5.6B |
| What is the current revenue of Bruker? | Bruker's last 12 months revenue is $3.4B. |
| What is the current revenue growth of Bruker? | Bruker revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Bruker? | Current revenue multiple of Bruker is 2.2x. |
| Is Bruker profitable? | Yes, Bruker is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bruker? | Bruker's last 12 months EBITDA is $627M. |
| What is Bruker's EBITDA margin? | Bruker's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Bruker? | Current EBITDA multiple of Bruker is 11.9x. |
| What is the current FCF of Bruker? | Bruker's last 12 months FCF is $208M. |
| What is Bruker's FCF margin? | Bruker's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Bruker? | Current FCF multiple of Bruker is 36.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
